Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.

IF 2.5 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-09-09 DOI:10.1007/s12094-025-04050-5

Giuseppa Scandurra, Filippo Marano, Vittorio Gebbia, Maria Rosaria Valerio, Daniela Sambataro, Valentina Lombardo, Giuseppe Angelico, Paolo Scollo, Giuseppe Scibilia, Alessandra Pizzo

{"title":"Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.","authors":"Giuseppa Scandurra, Filippo Marano, Vittorio Gebbia, Maria Rosaria Valerio, Daniela Sambataro, Valentina Lombardo, Giuseppe Angelico, Paolo Scollo, Giuseppe Scibilia, Alessandra Pizzo","doi":"10.1007/s12094-025-04050-5","DOIUrl":null,"url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life. This review summarizes current evidence on the incidence, pathophysiology, and clinical presentation of ADC-related ocular adverse events in gynecologic oncology. It also provides practical, evidence-based strategies for the prevention, monitoring, and management of these adverse events. Interventions include prophylactic topical therapies, supportive care measures, treatment delays or dose modifications, and herpes zoster vaccination. Comprehensive management of ocular toxicities is essential to ensure the safe and sustained use of ADCs, preserving both therapeutic benefit and patient well-being. Further research is warranted to optimize preventive and management protocols.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-04050-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life. This review summarizes current evidence on the incidence, pathophysiology, and clinical presentation of ADC-related ocular adverse events in gynecologic oncology. It also provides practical, evidence-based strategies for the prevention, monitoring, and management of these adverse events. Interventions include prophylactic topical therapies, supportive care measures, treatment delays or dose modifications, and herpes zoster vaccination. Comprehensive management of ocular toxicities is essential to ensure the safe and sustained use of ADCs, preserving both therapeutic benefit and patient well-being. Further research is warranted to optimize preventive and management protocols.

查看原文本刊更多论文

接受新型抗体-药物偶联物治疗的妇科癌症患者眼毒性的管理：一篇叙述性综述。

抗体-药物偶联物（adc）是一种很有前途的妇科癌症治疗方法，特别是卵巢癌和宫颈癌。mirvetuximab soravtansine和tisotumab vedotin等药物分别靶向叶酸受体α和组织因子，在选择有限的患者中报道了临床疗效。然而，它们的使用与眼部毒性有关，包括角膜病变、视力模糊和干眼，这可能影响依从性和生活质量。本文综述了目前有关妇科肿瘤adc相关眼部不良事件的发生率、病理生理学和临床表现的证据。它还为预防、监测和管理这些不良事件提供了实用的、基于证据的策略。干预措施包括预防性局部治疗、支持性护理措施、治疗延迟或剂量调整以及带状疱疹疫苗接种。眼部毒性的综合管理对于确保adc的安全和持续使用，保持治疗效果和患者健康至关重要。有必要进一步研究以优化预防和管理方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.